Alpelisib, Free Base, 500mg
Alpelisib (BYL-719) is a potent, selective, and orally bioavailable inhibitor of PI3Kα, designed to target cancers with PIK3CA mutations. It exhibits strong antineoplastic activity by selectively inhibiting the p110α isoform of PI3K, with an IC₅₀ of 5 nM, while showing significantly reduced activity against p110γ, p110δ, and p110β (IC₅₀ values of 250, 290, and 1200 nM, respectively). Alpelisib is widely used in cancer research and signaling pathway studies involving PI3K/AKT/mTOR.
